Flavia Mayer1, Laura Faglioni2, Nera Agabiti1, Susanna Fenu2, Francesco Buccisano3, Roberto Latagliata4, Roberto Ricci4, Maria Antonietta Aloe Spiriti5, Caterina Tatarelli5, Massimo Breccia4, Giuseppe Cimino6, Luana Fianchi7, Marianna Criscuolo7, Svitlana Gumenyuk8, Stefano Mancini9, Luca Maurillo3, Carolina Nobile10, Pasquale Niscola11, Anna Lina Piccioni12, Agostino Tafuri5, Giulio Trapè13, Alessandro Andriani14, Paolo De Fabritiis11, Maria Teresa Voso3, Marina Davoli1 and Gina Zini7
1 Department of Epidemiology, Lazio Regional Health Service (Italy).
2 Hematology Dep. Az. Osp. San Giovanni-Addolorata Rome (Italy).
3 Hematology Unit Tor Vergata University, Rome(Italy).
4 Dep of Cellular Biotechnology and Hematology, University “La Sapienza” Rome (Italy).
5 Hematology Unit Sant' Andrea Univ. "La Sapienza " Rome (Italy).
6 Dep. of Cellular Biotechnology and Hematology, University of Rome “Sapienza”–Polo Pontino, Latina (Italy).
7 Hematology Institute Università Cattolica del Sacro Cuore Rome (Italy).
8 Hematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute Rome (Italy).
9 Hematology Unit Az. Osp. San Camillo-Forlanini, Rome (Italy).
10 Hematology Dep. Campus Biomedico, Rome (Italy).
11 Hematology Unit Az. Osp. Sant Eugenio Rome (Italy).
12 Hematology Unit Az. Osp. Sandro Pertini, Rome (Italy).
13 Hematology Unit Az. Osp. Belcolle Viterbo (Italy).
14 Ospedale Nuova Regina Margherita, Rome (Italy).
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
on Myelodysplastic Syndromes (MDS) are difficult to collect by cancer
registries because of the lack of reporting and the use of different
classifications of the disease. In the Lazio Region, data from patients
with a confirmed diagnosis of MDS, treated by a hematology center, have
been collected since 2002 by the Gruppo Romano-Laziale Mielodisplasie
(GROM-L) registry, the second MDS registry existing in Italy.
Patients and Methods
|Table 1. Patients' characteristics according to the Lazio Hematology center where the diagnosis was made|
|Table 2. Frequency of patients who were enrolled by the GROM-L registry, with a correct anonymous patient code, who had at least 1 hospitalization episode during the period 2002-2012. (Numbers refers to the year of diagnosis).|
|Table 3. Distribution of the sub-diagnostic codes for 238.7 in 180 patients during various hospital admissions.|
|Table 4. Distribution of the principal diagnostic codes for the 203 hospitalization in 60 patients who had no hospitalization episodes with the ICD9-CM code 238.7 or another hematologic code.|
|Figure 1. Survival. A. Overall survival. B. Overall survival stratified by the type of MDS: In low-risk MDS, survival of RCMD and RARS are coincident until month 47 of follow-up, later-on the RCMD curve slightly fell. Survival of RA patients, compared to RCMD and RARS, shows a lower death rate before month 80 and higher afterwards. This might be influenced by the fact that RARS patients are fewer (N=28) than RCMD (N=129) and RA patients (N=195). In the high-risk group, death rates for RAEB II are higher at the beginning: 59% of RAEB II patients died by month 33 conversely to 49% of RAEB I patients.|
|Table 5. Distribution of deceased/survived patients by type of diagnosis.|
|Table 6. Distribution of patients alive stratified by year of diagnosis at one year follow up and at five years follow up.|
|Figure 2. Survival stratified by year of MDS diagnosis – 5 year follow-up.|
|Table 7. Distribution of the causes of death (ICD-9-CM coding) stratified by MDS subtype.|